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The microcirculation is regulated by oxygen gradients and by
endothelial release of nitric oxide, which can react with
hemoglobin to form S-nitroso derivatives. Here we induced
flow-mediated dilatation of the brachial artery in response to
ischemia in 141 non-diabetic patients with stage 3–4 chronic
kidney disease who had no history of smoking,
cardiovascular events or use of erythropoietin-based agents.
Patients with hemoglobin concentrations above the cohort
median of 11.6 g/dl were found to have significant reductions
in flow-mediated dilatation compared to those below the
median. This inverse relationship remained significant after
adjustment for potential confounders, including insulin
sensitivity, glomerular filtration rate, proteinuria, body mass
index, serum urate, etiology of underlying renal disease,
treatment with anti-hypertensive drugs, and traditional
Framingham risk factors. Given that hemoglobin can act as
an important nitric oxide carrier and buffer, our studies
suggest that the mechanism by which hemoglobin influences
the endothelium-dependent microcirculation requires its
nitrosylation; however, more direct studies need to be
performed.
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Anemia in chronic kidney disease (CKD) is currently
considered as a consequence of erythropoietin deficiency and
as an adaptive response to illness and inflammation.1 Although
it is plausible that physiological correction of erythropoietin
deficiency may be beneficial, studies in patients with CKD and
end-stage renal disease2–4 and a thorough meta-analysis5 have
coherently shown that full pharmacological correction of
anemia in this condition may produce harm. The excess risk
portended by anemia correction in CKD is currently attributed
to a noxious effect of higher doses of erythropoietin given the
none of erythropoietin resistance in patients with systemic
illness and inflammation.6 A hitherto still overlooked, addi-
tional mechanism may be related with the effects of red blood
cell mass and the concentration of the oxygen carrier molecule,
hemoglobin (Hb), on the vascular endothelium. Red cells
contribute to the regulation of vascular tone by viscosity/shear
stress-dependent and -independent mechanisms. Among these
mechanisms, the nitric oxide (NO)-carrying and -buffering
capacity of Hb appears prominent, because it modulates NO
bioavailability.7,8 This phenomenon depends on a series of
biochemical processes, including oxidation of NO and9
nitrosylation of the Fe molecule and of sulfur amino acids in
the globin molecule. The NO-carrying capacity of the Hb
molecule is considered as a phenomenon of paramount
biological relevance.8 The potential clinical relevance of Hb in
the regulation of NO bioavailability is suggested by the
observation that hematocrit exhibits a strong, independent
predictive power for cardiovascular disease events beyond
blood viscosity10 and by the finding that in polycythemia vera,
a disease characterized by increased red cell mass and high
blood viscosity, the endothelial response to vasodilatory stimuli
is much decreased.11 Furthermore, a strong inverse relationship
between the forearm blood flow response to acetylcholine and
Hb was recently reported in a series of type II diabetics with
modest or no anemia.
With this background in mind, we investigated whether
endothelial function defined on the basis of the forearm
blood flow in ischemia is associated with Hb concentration in
a large series of cardiovascular event-free, non-diabetic, non-
smoker, vitamin D-naive, and stage 3–4 CKD patients who
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had never received angiotensin-converting enzyme inhibitors
or angiotensin II blockers and whether such an association is
independent of classical and emerging risk factors, including
systemic inflammation, insulin sensitivity, serum calcium
and phosphate, and uric acid concentration.
RESULTS
The median Hb in the study population was 11.6 g per
100 ml. Demographic, clinical, and biochemical character-
istics in the whole study population and as categorized
according to the median Hb value are presented in Table 1.
Patients with Hb concentrations above the median displayed
higher systolic blood pressure as well as higher serum
triglyceride and insulin concentration and estimated glomer-
ular filtration rate levels. Flow-mediated dilatation (FMD)
was lower in patients with Hb above the median value. These
associations were also substantially confirmed by standard
regression analysis (Table 1). As shown in Figure 1, both
estimated glomerular filtration rate and proteinuria were
related with FMD. It is of note that Hb was inversely
associated with FMD, and each gram increase in the
concentration of this compound reflected a 2.0% decrease
in FMD. No significant difference was present between the
two groups in terms of age, gender, body mass index,
diastolic blood pressure, total, low-density lipoprotein (LDL)
and high-density lipoprotein (HDL) cholesterol, Home-
ostasis Model Assessment-Insulin resistance (HOMA-IR),
high sensitive C Reactive Protein, calcium, phosphate,
24-h proteinuria, endothelium-independent vasodilatation
(nitroglycerin-mediated dilatation, NMD), and uric acid
levels.
Multivariate analysis
To further analyze the independent contribution of Hb to
explain the variance of FMD, we constructed a series of
multiple regression models based on traditional and non-
traditional risk factors impacting on this variable. In the
unadjusted analysis, the Hb and FMD levels were intercorre-
lated (Figure 1 and Table 2). Adjustment for the full set of
Framingham risk factors did not significantly affect the
strength of the association. Further adjustment for glomerular
filtration rate (GFR), proteinuria, calcium, phosphate, hsCRP,
HOMA index, and the uric acid levels did not produce a
reduction in the strength of the association between Hb and
FMD, which remained relevant and highly significant. In the
final model, systolic blood pressure, LDL cholesterol, HOMA
index, proteinuria, and GFR resulted to be independent
correlates of FMD (Table 2). Forcing etiologies of CKD and
antihypertensive drugs into the final model did not materially
modify the correlation coefficient of the Hb–FMD relationship
(b¼0.28, Po0.001). There was no interaction between GFR
and proteinuria with Hb in explaining the variability in FMD.
Indeed, the Hb–FMD link was largely independent of the
absolute level of proteinuria or GFR (nonsignificant, NS) and
of similar degree in patients with and without proteinuria and
in patients with stages 3 and 4 CKD.
DISCUSSION
The main finding of this study is the presence of a negative
relationship between Hb and endothelial function in a series
of non-smoker, non-diabetic stage 3–4 CKD patients without
background cardiovascular complications. This association
was moderately strong and independent of established and
Table 1 | Demographic, hemodynamic, and biochemical data in non-diabetic CKD stage 3–4 patients categorized according to
median hemoglobin value (11.6 g per 100 ml)
CKD patients (n = 141) o11.6 g per 100 ml (n = 79) X11.6 g per 100 ml (n = 62) P-value
Age (years) 45±13 46±13 45±13 0.85
Male sex, n (%) 70 (49%) 34 (43%) 40 (55%) 0.35
BMI (kg/m2) 24.8±2.8 24.8±2.8 24.9±2.7 0.85
Systolic blood pressure (mm Hg) 134±9 131±9 136±8 0.001
Diastolic blood pressure (mm Hg) 85±4 84±5 85±4 0.55
On antihypertensive treatment Ca channel blocker: 16, 11%
a-blocker: 9, 6%
Diuretic: 4, 3%
Ca channel blocker: 9, 11%
a-blocker: 6, 8%
Diuretic: 4, 5%
Ca channel blocker: 7, 11%
a-blocker: 3, 5%
Diuretic: –
Calcium (mg per 100 ml) 8.4±0.5 8.4±0.4 8.4±0.5 0.87
Phosphate (mg per 100 ml) 4.7±1.2 4.7±1.1 4.7±1.1 0.91
LDL cholesterol (mg per 100 ml) 119±16 120±17 118±15 0.40
Glucose (mg per 100 ml) 87±10 90±9 84±10 0.02
Insulin (UI/l) 7.2±1.5 6.8±1.3 7.7±1.6 0.001
HOMA index 1.5±0.4 1.5±0.3 1.6±0.4 0.25
hsCRP (mg/l) 28 (16–58) 26 (16–58) 36 (17–58) 0.100
GFR (ml/min per 1.73m2) 33±13 31±13 36±14 0.035
Proteinuria (g/24 h) 1.3±0.5 1.3±0.5 1.3±0.5 0.79
Uric acid (g per 100 ml) 4.3±1.1 4.4±1.1 4.9±1.0 0.08
Hb (g per 100 ml) 11.4±1.1 10.7±0.7 12.7±0.8 o0.001
NMD (%) 13.0±0.5 13.0±0.5 12.9±0.5 0.27
FMD (%) 7.1±0.6 7.2±0.6 6.9±0.6 0.04
BMI, body mass index; CKD, chronic kidney disease; FMD, flow-mediated dilatation; GFR, glomerular filtration rate; Hb, hemoglobin; HOMA, Homeostasis Model Assessment;
NMD, nitroglycerin-mediated dilatation.
Data are expressed as mean±s.d., median (minimum–maximum), or as the percentage of frequency, as appropriate.
Significant values are highlighted in bold.
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novel risk factor for endothelial dysfunction. These observa-
tions may have potential relevance for the interpretation of
the excess risk caused by Hb normalization in CKD.
The median Hb concentration in this study (11.6 g per
100 ml) was similar to that in patients enrolled in the
Cardiovascular risk reduction by early anemia treatment by
epoetin beta study,3 the largest randomized study performed
so far in the CKD population with stage 3b–4 CKD. Crude
categorical analysis based on this value showed that FMD was
reduced in patients with Hb higher than the median value.
Further analysis by regression techniques revealed that the
best data fit of the Hb–FMD link was linear without any
apparent threshold value, indicating that such a link is
continuous over a Hb range between 8.5 and 14.5 g per
100 ml. It is of note that this association was unconfounded
by age, gender, fasting hyperglycemia or insulin resistance,
LDL cholesterol, smoking, arterial pressure, and inflamma-
tion. Neither GFR nor proteinuria or the diagnosis of renal
disease or antihypertensive treatment affected the Hb–FMD
link, which suggest that this phenomenon depends on a
peculiar effect of Hb per se on endothelial function regulation
rather than on confounding by renal disease severity and
other risk factors. This hypothesis is in keeping with earlier
studies reporting an even stronger Hb–endothelial function
association in type II diabetics12 and in essential hyperten-
sives as well (Perticone F, Maio R, Mastroianni S, Greco L,
Tripepi G, Mallamaci F, and Zoccali C. Hemoglobin and
endothelium-dependent vasodilation in uncomplicated, un-
treated subjects with essential hypertension (TH-PO251).
J Am Soc Nephrol 2008; 19(Suppl):165A, Abstract). Remark-
ably, in both diabetic and essential hypertensive patients
included in these studies, the inverse relationship between Hb
and the vasodilatory response of the endothelium was
evident over a range of Hb values narrower than that in
this study (11 to 15–16 g per 100 ml). Furthermore, in the
study by Natali et al.,12 Hb was inversely related to
endothelial function also in an analysis confined to
normotensive subjects, which is again in line with our
finding that adjustment for arterial pressure did not affect the
Hb–FMD link in CKD patients.
Our study in non-diabetic CKD 3–4 patients is the largest
performed so far exploring the Hb–endothelial function link
in human diseases. The observation that progressively higher
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Figure 1 | The association between FMD and Hb, GFR or 24-h
proteinuria in CKD 3 and 4 patients. (a) FMD and Hb, (b) FMD
and GFR, (c) FMD and 24-h proteinuria.
Table 2 | Multiple regression models of FMD in CKD 3 and 4
patients
Unadjusted
(b, P-value)
Model 1
(b, P-value)
Model 2
(b, P-value)
Hemoglobin (g per
100 ml)
0.33 (o0.001) 0.26 (0.002) 0.28 (o0.001)
Age (years) 0.049 (0.56) 0.032 (0.77)
Sex 0.012 (0.89) 0.034 (0.69)
BMI (kg/m2) 0.043 (0.61) 0.043 (0.62)
SBP (mm Hg) 0.25 (0.002) 0.37 (o0.001)
LDL cholesterol (mg
per 100 ml)
0.23 (0.003) 0.16 (0.01)
Glucose (mg per
100 ml)
0.067 (0.44) 0.07 (0.32)
HOMA index 0.14 (0.03)
hsCRP (mg/l) 0.068 (0.43)
GFR (ml/min per
1.73m2)
0.54 (o0.001)
Proteinuria (g/24 h) 0.16 (0.01)
Ca (mg per 100 ml) 0.051 (0.55)
P (mg per 100 ml) 0.054 (0.53)
Uric acid (g per
100 ml)
0.128 (0.14)
BMI, body mass index; Ca, calcium; CKD, chronic kidney disease; GFR, glomerular
filtration rate; HOMA, Homeostasis Model Assessment; P, phosphate; LDL, low-density
lipoprotein; SBP, systolic blood pressure. Significant values highlighted in bold.
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Hb levels signal an increasing risk for endothelial dysfunction
may depend on the peculiar role of Hb as a NO buffer/carrier
and/or on other factors. Owing to NO oxidation,13
nitrosylation of the Fe molecule, and linkage to sulfur amino
acids in the globin molecule, Hb acts as a transient or
permanent NO buffer, thus modulating NO bioavailability.7,8
It is well demonstrated that NO liberated from the
endothelium is taken up and transported by red blood cells
as S-nitrosohemoglobin and in other chemical forms.8 The
S-nitrosohemoglobin binding is fully reversible and NO by
S-nitrosylated Hb represents an important biological me-
chanism in the response to tissue hypoxia.8 However,
S-nitrosylated Hb releases NO when oxygen is extracted
from arterial blood, a phenomenon occurring at the capillary
level, that is, posterior to arterioles, which is the main site
where vasoregulation is controlled. On the other hand, NO
oxidation by Hb and the Fe–NO link are not reversible, thus
affecting the vasodilatory potential of the NO molecule. It is
of note that it was emphasized that oxidative stress—a
pervasive phenomenon in CKD—may limit the release of NO
from the Hb molecule.8 Furthermore, NO bioavailability is
compromised in patients with CKD,14,15 which can make
these patients more prone to any negative effect of NO
buffering by Hb. Endothelial dysfunction in CKD is typically
GFR and proteinuria-dependent, a phenomenon once again
confirmed in this study. Even though NO buffering by Hb
seems to be a cogent interpretation of our findings, other
interpretations are possible. Reduction in Hb level results in
the upregulation of eNOS, a phenomenon evident systemi-
cally and at renal level in a model of iron deficiency anemia in
the rat.16 Thus, it is possible that, rather than high Hb levels
impair the endothelial response to vasodilatory stimuli, low
Hb levels enhance the same response. As a third possibility,
relatively higher Hb levels in CKD patients may represent a
surrogate marker for diffuse endothelial dysfunction, which
at the kidney level can stimulate erythropoietin production
and hence increase Hb by promoting renal vasoconstriction.
Even though this hypothesis cannot be excluded only on the
basis of our cross-sectional data, neither the GFR level nor
proteinuria appeared to be modifiers of the Hb–FMD
relationship, suggesting that the Hb–endothelial function
link does not depend on the fact that Hb is a mere marker of
renal disease severity. Our findings are apparently in contrast
with recent observations by London et al.17 in end-stage renal
disease, showing an improvement in endothelium-dependent
vasodilatation in patients with moderate-to-severe degree of
anemia (9.4 g per 100 ml on average) when Hb was increased
to an average level of Hb coinciding with the upper limit of
Hb target recommended by the guidelines (12 g per 100 ml).
End-stage renal disease patients are a very high-risk population,
and severe anemia in these patients is definitely a maladaptative
phenomenon.18 The improvement registered in London’s paper
conforms with early erythropoietin studies in end-stage renal
disease patients showing an improvement in cardiovascular risk
profile (as reflected by a marked reduction in left ventricular
mass) when severe anemia was partially corrected (to reach an
average 10 g per 100 ml value).19–20 Patients in our study were
low-risk CKD patients (non-diabetic, non-smokers, cardiovas-
cular event-free), and the vast majority of them had Hb values
in the 10–15 g per 100 ml range.
This study has limitations. On account of the cross-
sectional nature, we cannot interpret the Hb—FMD link in
causal terms. As alluded to above, endothelial dysfunction at
kidney level may cause vasoconstriction and by this
mechanism stimulate erythropoietin synthesis and increase
the Hb level. Apart from our observations showing that the
Hb–FMD link is largely independent of the severity of renal
disease, studies in experimental models apparently do not
support this interpretation. Indeed, the endothelial NO
synthase null mouse, that is, an animal model with severe
systemic endothelial dysfunction,21 does not develop poly-
cythemia, as one would expect if endothelial dysfunction at
renal level triggers erythropoietin synthesis through local
ischemia and hypoxia. Even though an effect of Hb per se on
endothelial function in vivo in humans is fully compatible,
the present cross-sectional data in CKD and with the earlier-
mentioned observations in other conditions12 (Perticone F,
Maio R, Mastroianni S, Greco L, Tripepi G, Mallamaci F, and
Zoccali C. Hemoglobin and endothelium-dependent vasodi-
lation in uncomplicated, untreated subjects with essential
hypertension (TH-PO251). J Am Soc Nephrol 2008; 19(Sup-
pl):165A, Abstract), it should be clearly recognized that the
balance between NO synthesized by the endothelium and NO
taken-up red blood cell has not been studied in detail in
humans. Thus, our data in CKD patients as well as the earlier
above-mentioned observations in type II diabetics and in
essential hypertensive subjects should be considered as
hypothesis generating rather than as hypothesis testing.
In conclusion, the results of this study in a well-selected
series of non-diabetic CKD patients show that, independent
from classical and emerging risk factors, higher Hb values are
associated with reduced endothelium-dependent vasodilata-
tion in this population. Whatever the explanation, the
association of endothelial dysfunction with relatively higher
Hb levels in patients with CKD is of potential relevance for
the interpretation of the increased cardiovascular risk elicited
by Hb normalization in CKD. Specifically designed mechan-
istic studies are warranted to clarify the nature of the
endothelial function–Hb link in CKD.
MATERIALS AND METHODS
Patients
Between May 2005 and May 2008, a total number of 350 patients
with CKD stage 3–4 were referred to the Nephrology outpatient
clinics of Gulhane School of Medicine. By protocol, we aimed at
testing endothelial function in non-diabetic, non-smoker patients
without background cardiovascular complications (coronary artery
disease, congestive heart failure, or peripheral vascular disease).
From this group, we selected 201 non-diabetic patients as the
candidates for the study. Patients who were being treated with
angiotensin-converting enzyme inhibitors (n¼ 33), angiotensin
receptor blockers (n¼ 21), statins (n¼ 13), vitamin D (n¼ 10), or
supplemental vitamin pills (n¼ 7) at the time of the study were
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excluded. No patient was on treatment with erythropoietin-
stimulating agents. Finally, 141 non-diabetic patients, classified as
Kidney Disease Outcomes Quality Initiative stage 3 (n¼ 70) and
stage 4 (n¼ 71), were enrolled for this study. None had acute
infections at the time of the study. Part of the data was published
elsewhere.22
Patients were studied before starting pharmacological treatment
aimed at preventing renal disease progression and complications of
CKD. The etiologies of the patients were as follows: glomerulone-
phritis (n¼ 33), hypertensive nephropathy (n¼ 31), chronic
pyelonephritis (n¼ 11), reflux nephropathy (n¼ 6), autosomal-
polycystic kidney disease (n¼ 10), and unknown (n¼ 50). Of these
patients, 16 were taking calcium channel blockers, 9 were taking
a-blockers, 4 were taking diuretics. As alluded to above, owing to
the peculiar referral pattern to Gulhane Medical Center preliminary
nephrology consultation: is considered before specific drug pre-
scription to patients with suspected renal diseases. Brachial artery
endothelium-dependent vasodilatation (FMD) was studied. The
Ethical Committee of Gulhane School of Medicine (Etlik-Ankara,
Turkey) approved the study, and all patients gave their informed
consent.
Laboratory measurements
Arterial blood pressure was measured by a physician three times
after a 15-min resting period in the morning, and mean values were
calculated for systolic and diastolic pressures for all subjects. All
samples were obtained from patients in the morning after 12 h of
fasting, for measurement of fasting plasma glucose (FPG), serum
albumin, total serum cholesterol, triglycerides, high-density lipo-
protein, LDL cholesterol, calcium, and phosphate. Total plasma
cholesterol, triglycerides, and high-density lipoprotein cholesterol
were measured by the enzymatic colorimetric method with Olympus
AU 600 autoanalyzer using reagents from Olympus Diagnostics
GmbH (Hamburg, Germany). LDL cholesterol was calculated by
Friedewald’s formula.23 A 24-h urine collection was carried out three
times, and the average of three 24-h proteinuria measurements was
taken as the representative of each participant’s 24-h protein
excretion rate.
Patients were classified with respect to estimated glomerular
filtration rate calculated according to the simplified version of the
Modification of Diet in Renal Disease formula as defined by Levey
et al:24 [GFR¼ 186Pcr1.154 age0.203 1.212 (if black) 0.742
(if female)].
The serum basal insulin value was determined by the coated tube
method (DPC-USA). HOMA-IR was computed by the following
formula:25 HOMA-IR¼ FPG (mg per 100 ml) immunoreactive
insulin (mIU/ml)/405. Serum total calcium was measured by the
Cresolphthalein complex-one method using Menagent Calcium 60 s
kits (Menarini Diagnostics, Florence, Italy). Serum phosphorus was
measured by the ammonia molybdate complex method using
Menagent Phosphofix kits (Menarini Diagnostics). To measure
hsCRP, serum samples were diluted at a ratio of 1:101 with the
diluents solution. Calibrators, kit controls, and serum samples were
all added on each microwell with an incubation period of 30 min.
After three washing intervals, 100 ml enzyme conjugate (peroxidase-
labeled anti-CRP) was added on each microwell for additional
15 min incubation in room temperature in dark. The reaction was
stopped with a stop solution, and photometric measurement was
performed at the 450 nm wavelength. The amount of serum samples
was calculated as mg/l using a graph plotted by noting the
absorbance levels of the calibrators.
Vascular assessment
Endothelium-dependent flow-mediated vasodilatation and endothe-
lium-independent vasodilatation (NMD) of the brachial artery were
assessed non-invasively, using high-resolution ultrasound as de-
scribed by Celermajer et al.26. The method for the vascular
assessment met the criteria that were mentioned by the International
Brachial Artery Reactivity Task Force.27
Measurements performed made by a single observer using an
ATL 5000 ultrasound system (Advanced Technology Laboratories
Inc., Bothell, WA, USA) with a 12-MHz prob. All vasoactive
medications were withheld for 24 h before the procedure. The
subjects remained at rest in the supine position for at least 15 min
before the examination started. Subject’s arm was comfortably
immobilized in the extended position to allow consistent recording
of the brachial artery 2–4 cm above the antecubital fossa. Three
adjacent measurements of end-diastolic brachial artery diameter
were performed from single two-dimensional frames. All ultrasound
images were recorded on an S-VHS videotape for subsequent
blinded analysis. A pneumatic tourniquet was inflated to
300 mm Hg with obliteration of the radial pulse. After 5 min, the
cuff was deflated. Flow measurements were performed 60 s after
deflation. After a further 15 min, measurements were repeated, and
again 3 min after the administration of sublingual glyceryl trinitrate
(400 mg). The maximum FMD and NMD diameters were calculated
as the average of the three consecutive maximum diameter
measurements after hyperemia and nitroglycerin, respectively. The
FMD and NMD were then calculated as the percent change in
diameter compared with baseline resting diameters.
Statistical analysis
All the statistical analyses were performed by using SPSS 11.0 (SPSS
Inc., Chicago, IL, USA) statistical package. Non-normally distrib-
uted variables were expressed as median (range) and normally
distributed variables were expressed as mean±s.d., as appropriate. A
P-value o0.05 was considered to be statistically significant.
Differences among the groups were analyzed by the Student t-test
(continuous variables) and the w2 test (categorical variables).
Standard correlation analysis was used for testing associations
between paired variables. Finally, multiple regression analysis was
applied to test the independent link between FMD and potential
functional correlates of this variable. To this scope, we computed
models of increasing complexity adjusting for traditional (Framing-
ham risk factors) and emerging risk factors, as well as for the
diagnosis of renal disease and anti-hypertensive medication type.
Multivariate models included at least 10 observations for each
covariate in the same models.28
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